Key result
Fondaparinux generates anti-PF4 antibodies similarly to enoxaparin but causes zero cases of clinical HIT.
RCT (n=2,726)
Answers are grounded in this paper and cite their sources.
Heparin-induced thrombocytopenia (HIT) is caused by platelet-activating IgG antibodies that recognize platelet factor 4 (PF4) bound to heparin. Immunogenicity of heparins differs in that unfractionated heparin (UFH) induces more anti-PF4/heparin antibodies than low-molecular-weight heparin (LMWH) and UFH also causes more HIT. Fondaparinux, a synthetic anticoagulant modeled after the antithrombin-binding pentasaccharide, is believed to be nonimmunogenic. We tested 2726 patients for anti-PF4/heparin antibodies after they were randomized to receive antithrombotic prophylaxis with fondaparinux or LMWH (enoxaparin) following hip or knee surgery. We also evaluated in vitro cross-reactivity of the IgG antibodies generated against PF4 in the presence of UFH, LMWH, danaparoid, or fondaparinux. We found that anti-PF4/heparin antibodies were generated at similar frequencies in patients treated with fondaparinux or enoxaparin. Although antibodies reacted equally well in vitro against PF4/UFH and PF4/LMWH, and sometimes weakly against PF4/danaparoid, none reacted against PF4/fondaparinux, including even those sera obtained from patients who formed antibodies during fondaparinux treatment. At high concentrations, however, fondaparinux inhibited binding of HIT antibodies to PF4/polysaccharide, indicating that PF4/fondaparinux interactions occur. No patient developed HIT. We conclude that despite similar immunogenicity of fondaparinux and LMWH, PF4/fondaparinux, but not PF4/LMWH, is recognized poorly by the antibodies generated, suggesting that the risk of HIT with fondaparinux likely is very low.
No takes yet. Share an insight, caveat, or question.
Warkentin et al. (2005) conducted an RCT in Patients requiring antithrombotic prophylaxis following hip or knee surgery (n=2,726). Fondaparinux vs. LMWH (enoxaparin) was evaluated on Generation of anti-PF4/heparin antibodies and development of HIT. Fondaparinux generated anti-PF4/heparin antibodies at similar frequencies to enoxaparin, but the antibodies poorly recognized PF4/fondaparinux, and 0 patients developed clinical HIT.
Synapse has enriched 10 related papers. Consider them for comparative context: